tbuckley/cabot-search huggingface dataset:
Potential Theranostics Application of Bio-Synthesized Silver Nanoparticles (4-in-1 System)
Authors: Sudip Mukherjee, Debabrata Chowdhury, Rajesh Kotcherlakota, Sujata Patra, Vinothkumar B, Manika Pal Bhadra, Bojja Sreedhar, Chitta Ranjan Patra
Journal: Theranostics (2014)

In this report, we have designed a simple and efficient green chemistry approach for the synthesis of colloidal silver nanoparticles (b-AgNPs) that is formed by the reduction of silver nitrate (AgNO 3 ) solution using Olax scandens leaf extract.The colloidal b-AgNPs, characterized by various physico-chemical techniques exhibit multifunctional biological activities (4-in-1 system).Firstly, bio-synthesized silver nanoparticles (b-AgNPs) shows enhanced antibacterial activity compared to chemically synthesize silver nanoparticles (c-AgNPs).Secondly, b-AgNPs show anti-cancer activities to different cancer cells (A549: human lung cancer cell lines, B16: mouse melanoma cell line & MCF7: human breast cancer cells) (anti-cancer).Thirdly, these nanoparticles are biocompatible to rat cardiomyoblast normal cell line (H9C2), human umbilical vein endothelial cells (HUVEC) and Chinese hamster ovary cells (CHO) which indicates the future application of b-AgNPs as drug delivery vehicle.Finally, the bio-synthesized AgNPs show bright red fluorescence inside the cells that could be utilized to detect the localization of drug molecules inside the cancer cells (a diagnostic approach).All results together demonstrate the multifunctional biological activities of bio-synthesized AgNPs (4-in-1 system) that could be applied as (i) anti-bacterial & (ii) anti-cancer agent, (iii) drug delivery vehicle, and (iv) imaging facilitator.To the best of our knowledge, there is not a single report of biosynthesized AgNPs that demonstrates the versatile applications (4-in-1 system) towards various biomedical applications.Additionally, a plausible mechanistic approach has been explored for the synthesis of b-AgNPs and its anti-bacterial as well as anti-cancer activity.We strongly believe that bio-synthesized AgNPs will open a new direction towards various biomedical applications in near future.
Persistent Differences Among Centers Over 3 Years in Glycemic Control and Hypoglycemia in a Study of 3,805 Children and Adolescents With Type 1 Diabetes From the Hvidøre Study Group
Authors: Thomas Danne, Henrik B. Mortensen, Philip Hougaard, Helle Lynggaard, Henk-Jan Aanstoot, Francesco Chiarelli, Denis Daneman, Harry Dorchy, Patrick Garandeau, Stephen A. Greene, Hilary Hoey, Reinhard W. Holl, Eero A. Kaprio, Mirjana Kocova, Pedro Martul, Nobuo Matsuura, Kenneth J. Robertson, Eugen J. Schoenle, Oddmund Søvik, Peter G.F. Swift, Rosa M. Tsou, Maurizio Vanelli, Jan Åman
Journal: Diabetes Care (2001)

OBJECTIVE—Twenty-one international pediatric diabetes centers from 17 countries investigated the effect of simple feedback about the grand mean HbA1c level of all centers and the average value of each center on changes in metabolic control, rate of severe hypoglycemia, and insulin therapy over a 3-year period. RESEARCH DESIGN AND METHODS—Clinical data collection and determination of HbA1c levels were conducted at a central location in 1995 (n = 2,780, age 0–18 years) and 1998 (n = 2,101, age 11–18 years). RESULTS—Striking differences in average HbA1c concentrations were found among centers; these differences remained after adjustment for the significant confounders of sex, age, and diabetes duration. They were apparent even in patients with short diabetes duration and remained stable 3 years later (mean adjusted HbA1c level: 8.62 ± 0.03 vs. 8.67 ± 0.04 [1995 vs. 1998, respectively]). Three centers had improved significantly, four centers had deteriorated significantly in their overall adjusted HbA1c levels, and 14 centers had not changed in glycemic control. During the observation period, there were increases in the adjusted insulin dose by 0.076 U/kg, the adjusted number of injections by 0.23 injections per day, and the adjusted BMI by 0.95 kg/m2. The 1995 versus 1998 difference in glycemic control for the seven centers could not be explained by prevailing insulin regimens or rates of hypoglycemia. CONCLUSIONS—This study reveals significant outcome differences among large international pediatric diabetes centers. Feedback and comparison of HbA1c levels led to an intensification of insulin therapy in most centers, but improved glycemic control in only a few.
Immune status in Crohn's disease : 3. Peripheral blood B lymphocytes, enumerated by means of F(ab)2-antibody fragments, Null and T lymphocytes
Authors: I. O. Auer, S. Gotz, E. Ziemer, H. Malchow, H. Ehms
Journal: Gut (1979)

In the peripheral blood of patients with Crohn9s disease (CD) the numerical distribution of the three major B lymphocyte subsets was determined by the identification of surface immunoglobulins using F(ab)<sub>2</sub>-antibody fragments. T cell counts were also obtained and the number of null cells was calculated. Twenty-eight patients with Crohn9s disease including 14 patients with previously untreated and very short-standing disease (group CD 1) and 14 patients with long-standing and/or previous drug treated disease (group CD 2) were compared with 28 sex and age-matched normals as well as with 13 patients with acute inflammatory bowel disease (group D). Patients in group D and inactive patients of group CD 1 showed a significant absolute lymphocytosis due to an increase in both the three B cell subsets and the T cells, without changes in the null cells. While the proportion of T cells was normal, there was a significant relative B lymphocytosis and a relative null cytopenia in these patients. Active CD 1 patients, however, showed significantly lower absolute lymphocyte and T cell numbers. In group CD 2, there was a significant absolute lymphopenia caused by an equal decrease in B and T cells. Highly active CD 2 patients showed higher absolute null cell counts than inactive patients. With increasing disease duration there was a significant decrease of the relative and absolute B cell concentrations. The data obtained suggest that T and B cell populations in the peripheral blood are reduced in certain patients with Crohn9s disease and that this occurs secondarily to activity of disease, chronicity of disease, and the effects of therapy.
Coevolution of Prostate Cancer and Bone Stroma in Three-Dimensional Coculture: Implications for Cancer Growth and Metastasis
Authors: Shian-Ying Sung, Chia-Ling Hsieh, Andrew Law, Haiyen E. Zhau, Sen Pathak, Asha S. Multani, Sharon Lim, Ilsa M. Coleman, Li-Chin Wu, William D. Figg, William L. Dahut, Peter Nelson, Jae K. Lee, Mahul B. Amin, Robert Lyles, Peter A.J. Johnstone, Fray F. Marshall, Leland W.K. Chung
Journal: Cancer Research (2008)

Abstract Human bone stromal cells, after three-dimensional coculture with human prostate cancer (PCa) cells in vitro, underwent permanent cytogenetic and gene expression changes with reactive oxygen species serving as mediators. The evolved stromal cells are highly inductive of human PCa growth in mice, and expressed increased levels of extracellular matrix (versican and tenascin) and chemokine (BDFN, CCL5, CXCL5, and CXCL16) genes. These genes were validated in clinical tissue and/or serum specimens and could be the predictors for invasive and bone metastatic PCa. These results, combined with our previous observations, support the concept of permanent genetic and behavioral changes of PCa epithelial cells after being either cocultured with prostate or bone stromal cells as three-dimensional prostate organoids or grown as tumor xenografts in mice. These observations collectively suggest coevolution of cancer and stromal cells occurred under three-dimensional growth condition, which ultimately accelerates cancer growth and metastasis. [Cancer Res 2008;68(23):9996–10003]
Pustular vasculitis in a patient with T-cell large granular lymphocyte proliferation and myelodysplasia. Successful treatment by ciclosporin
Authors: L. Sailler, K. Joseph-Hein, L. Astudillo, S. Madaule, M. Ecoiffier, S. Dahan, M.B. Delisle, P. Arlet
Journal: British Journal of Dermatology (2003)

Sir, Noninfectious pustulosis is rare. We present a case associated with myelodysplasia and a T‐cell large granular lymphocyte (T‐LGL) proliferation. Skin biopsy showed vasculitic lesions. Both the pustulosis and the myelodysplasia were successfully controlled by ciclosporin. A 76‐year‐old man was hospitalized in January 1996 because of asthenia and diffuse pain. He was receiving atenolol and amlodipine for hypertension. Clinical examination was normal. A haemogram showed white blood cell count 7·9 × 109 L−1; haemoglobin (Hb) 9·1 g dL−1; lymphocytes 1·76 × 109 L−1; platelets 118 × 109 L−1; mean corpuscular volume (MCV) 114 fL; reticulocytes 26 × 109 L−1. Sixty‐seven per cent of the blood lymphocytes were LGLs. Erythrocyte sedimentation rate was 154 mm in the first hour. Marrow smears revealed medullary myelodysplasia and an LGL infiltrate, corresponding to 49% of the marrow lymphocytes. Marrow trephine biopsy showed a diffuse lymphocytic infiltrate, phenotype CD3+CD8–CD56–, suggestive of a T‐LGL lymphoproliferation. Chest X‐ray and abdominal ultrasound were normal.
Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells
Authors: Peter E. Fecci, Alison E. Sweeney, Peter M. Grossi, Smita K. Nair, Christopher A. Learn, Duane A. Mitchell, Xiuyu Cui, Thomas J. Cummings, Darell D. Bigner, Eli Gilboa, John H. Sampson
Journal: Clinical Cancer Research (2006)

Abstract Purpose: Elevated proportions of regulatory T cells (Treg) are present in patients with a variety of cancers, including malignant glioma, yet recapitulative murine models are wanting. We therefore examined Tregs in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct. Experimental Design: CD4+CD25+Foxp3+GITR+ Tregs were quantified in the peripheral blood, spleens, cervical lymph nodes, and bone marrow of mice bearing malignant glioma. The capacities for systemic anti-CD25 therapy to deplete Tregs, enhance lymphocyte function, and generate antiglioma CTL responses were assessed. Lastly, survival and experimental allergic encephalitis risks were evaluated when anti-CD25 was combined with a dendritic cell–based immunization targeting shared tumor and central nervous system antigens. Results: Similar to patients with malignant glioma, glioma-bearing mice show a CD4 lymphopenia. Additionally, CD4+CD25+Foxp3+GITR+ Tregs represent an increased fraction of the remaining peripheral blood CD4+ T cells, despite themselves being reduced in number. Similar trends are observed in cervical lymph node and spleen, but not in bone marrow. Systemic anti-CD25 administration hinders detection of CD25+ cells but fails to completely eliminate Tregs, reducing their number only moderately, yet eliminating their suppressive function. This elimination of Treg function permits enhanced lymphocyte proliferative and IFN-γ responses and up to 80% specific lysis of glioma cell targets in vitro. When combined with dendritic cell immunization, anti-CD25 elicits tumor rejection in 100% of challenged mice without precipitating experimental allergic encephalitis. Conclusions: Systemic anti-CD25 administration does not entirely eliminate Tregs but does prevent Treg function. This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and Treg compartments seen in patients with malignant glioma.
Abstract P1-15-12: Single Nucleotide Polymorphism (SNP) Bayesian networks (BNs) Predict Risk of Chemotherapy-Induced Side Effects in Patients with Breast Cancer Receiving Dose Dense (DD) Doxorubicin/Cyclophosphamide Plus Paclitaxel (AC+T)
Authors: LS Schwartzberg, ST Sonis, MS Walker, SM Weidner, G Alterovitz
Journal: Cancer Research (2012)

Abstract Background: Despite advances in supportive care, patients undergoing standard chemotherapy for breast cancer are at significant, but unequal, risk for the development of treatment-induced side effects. Current methods for predicting risk are inconsistent and unreliable. Because the pathobiology of many side effects are regulated by the synergistic interaction of simultaneously expressed genes, we reasoned that a novel approach to risk prediction could be achieved by the development of clusters of SNPs defined by BNs. The present study was designed to assess the feasibility of identifying BNs that were associated with regimen-related diarrhea, oral mucositis, nausea and vomiting, fatigue, cognitive dysfunction and neuropathy in patients with breast cancer treated with dose-dense AC+T. The primary endpoint was an area under the receiver operating characteristic curve (aROC) &amp;gt;0.80. Methods: After informed consent, 78 patients with breast cancer who had received at least 3 cycles of (DD) AC+T were enrolled and saliva samples were collected. Salivary DNA was isolated and analyzed on Illumina Omni microarrays (2.5 × 106 SNPs). Standard supportive therapy for prevention and management of side effects was provided. The frequency and severity of diarrhea, oral mucositis, fatigue, cognitive dysfunction, neuropathy&amp;lt;INS dateTime=2012-09-25T18:35 cite=“mailto:CJordan”&amp;gt;,&amp;lt;/INS&amp;gt; and nausea and vomiting were determined using Patient Care Monitor©, a validated patient-reported symptom assessment instrument. BNs were developed for each of the six side effects using Bayesian methods including ten-fold internal cross-validation. Results: The incidence of clinically significant side effects was higher than anticipated by the literature and are reported in Table 1 along with the accuracy and aROC. Conclusions: We identified SNP-BNs associated with moderate to severe common side effects of AC+T regimens used to treated breast cancer. These BNs, sourced from salivary SNPs, should provide &amp;lt;/DEL&amp;gt; clinicians with accurate actionable information which predicts side effect risk for patients who are scheduled to receive dose-dense doxorubicin/cyclophosphamide and paclitaxel for the treatment of breast cancer. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-15-12.
Delayed pneumothorax after transbronchial lung biopsy.
Authors: H Levy, J M Kallenbach, C Feldman, P Pincus, M Hurwitz
Journal: Thorax (1986)

The complication and mortality rate associated with fibreoptic bronchoscopy and transbronchial lung biopsy are low.' 2 Pneumothorax has been reported to occur after about 5% of transbronchial lung biopsies and is the most common complication of the procedure.3-Many extensive reviews of fibreoptic bronchoscopy with transbronchial biopsy, however, make no mention of the occurrence of delayed pneumothorax after the procedure.'-'We report two patients who suffered delayed pneumothoraces after transbronchial lung biopsies. Case reportsCase I A 15 year old recipient of a renal transplant was admitted to hospital with pneumonia suspected to be due to Pneumo- cystis carinii.She was being treated with prednisone and azathioprine.Examination showed her to be confused, cyanosed, and febrile, with diffuse crepitations audible.The chest radiograph showed a bilateral infiltrate, more notice- able on the left.Multiple transbronchial lung biopsies of the left lung were performed through a fibreoptic bronchoscope with fluoro- scopic guidance under general anaesthesia with muscle relaxants.Examination of the biopsy specimens showed the alveolar spaces to contain a granular exudate with cysts of Pneumocystis carinii.Treatment was started with intravenous sulphamethoxazole 800 mg and trimethoprim 160 mg administered eight hourly.Fluoroscopy of the chest and an erect expiratory chest radiograph, performed immediately after the procedure, and the chest radiograph obtained the following morning showed no evidence of pneumothorax.Thirty six hours after the biopsy the patient became acutely distressed.The chest radiograph showed a large left sided pneumothorax.Despite the insertion of an intercostal drain her condition deterio- rated and mechanical ventilation was instituted.After a complicated 18 day course extubation was possible.The pulmonary infiltrate progressively cleared radiologically and the patient was discharged from hospital.Case 2 A 28 year old nursing sister was admitted to hospital with a three month history of weight loss and dry cough.Chest radiographs showed progressive consolidation of the pos- terior segment of the left upper lobe.Because the sputum was persistently negative for acid fast bacilli and other bacte-
POEMS syndrome: definitions and long-term outcome
Authors: Angela Dispenzieri, Robert A. Kyle, Martha Q. Lacy, S. Vincent Rajkumar, Terry M. Therneau, Dirk R. Larson, Philip R. Greipp, Thomas E. Witzig, Rita Basu, Guillermo A. Suarez, Rafael Fonseca, John A. Lust, Morie A. Gertz
Journal: Blood (2003)
Regression of Collateral Function After Recanalization of Chronic Total Coronary Occlusions
Authors: Gerald S. Werner, Ulf Emig, Oliver Mutschke, Gero Schwarz, Philipp Bahrmann, Hans R. Figulla
Journal: Circulation (2003)

Collaterals can maintain myocardial function or preserve viability in chronic total coronary occlusions (CTOs). It is unknown whether and to what extent collaterals regress after successful recanalization of a CTO.In 103 patients with successful recanalization of a CTO collateral function was assessed by intracoronary Doppler and pressure recordings before and after recanalization, and again after 5.0+/-1.3 months. Doppler (CFI) and pressure-derived collateral function indexes (CPI) and collateral (RColl) and peripheral resistance indexes (RP) were calculated. In 10 patients with reocclusion, all without myocardial infarction during follow-up, collateral function had reached a similar level as before the first recanalization. In the other 93 patients with or without restenosis, collateral function was attenuated during follow-up. CPI had decreased by 23% immediately after recanalization (P<0.001) and decreased further by another 23% at follow-up (P<0.001). The RColl increased immediately after recanalization by 82% (P<0.001) and by a further 273% at follow-up (P<0.001). In contrast, RP increased only by 22% after recanalization (P<0.001) and by an additional 12% at follow-up (P<0.05). The initial size of the collaterals but not the incidence of a restenosis influenced the collateral regression. Only 18% of patients at follow-up had collaterals with a CPI >0.30, presumably sufficient to prevent ischemia during acute occlusion.Collateral function regresses during long-term follow-up, especially in collaterals with a small diameter. In the majority of patients, collaterals are not readily recruitable in the case of acute occlusion. However, collaterals have the potential to recover in the case of chronic reocclusion.
Demonstration of a second ligand for the low affinity receptor for immunoglobulin E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes.
Authors: S Pochon, P Graber, M Yeager, K Jansen, A R Bernard, J P Aubry, J Y Bonnefoy
Journal: The Journal of Experimental Medicine (1992)

Recombinant full-length human CD23 has been incorporated into fluorescent liposomes to demonstrate the existence of a ligand for CD23 that is different from the previously known ligand, immunoglobulin E (IgE). The novel ligand for CD23 is expressed on subsets of normal T cells and B cells as well as on some myeloma cell lines. The interaction of full-length CD23 with its ligand is specifically inhibited by anti-CD23 monoclonal antibodies and by IgE, and it is Ca2+ dependent. Moreover, tunicamycin treatment of a CD23-binding cell line, RPMI 8226, significantly reduced the binding of CD23 incorporated into fluorescent liposomes, and a sugar, fucose-1-phosphate, was found to inhibit CD23-liposome binding to RPMI 8226 cells, suggesting the contribution of sugar structures on the CD23 ligand. In addition, CD23-transfected COS cells were shown to form specific conjugates with the cell line RPMI 8226. These data demonstrate that CD23 interacts with a ligand, which is different from IgE, and that CD23 can be considered as a new surface adhesion molecule involved in cell-cell interactions.
The ICIDH-2 as a framework for the assessment of functioning and disability in rheumatoid arthritis
Authors: J Fransen
Journal: Annals of the Rheumatic Diseases (2002)

Objective: To investigate by a cross sectional study in patients with rheumatoid arthritis (RA) the relationship between measures of impairment, activity limitation, and participation of the model of functioning and disability (ICIDH-2). Methods: Inclusion data of patients with RA (n=803) from the Swiss Clinical Quality Management Group were used. Impairments were measured by the Short Form-36 (SF-36) bodily pain scale, rheumatoid arthritis disease activity index (RADAI), disease activity score (DAS28), and radiographic scoring (<i>x</i> ray). Activity limitation was measured with the Health Assessment Questionnaire (HAQ) and the SF-36 physical functioning scale. Participation was measured with the SF-36 role and social functioning scales. Spearman (partial) correlations were used for analysis. Results: Impairment and activity limitation dimensions of the ICIDH-2 model are related; correlations with the HAQ were: SF-36 bodily pain (<i>r</i><sub>s</sub>=−0.61), RADAI (<i>r</i><sub>s</sub>=0.58), DAS28 (<i>r</i><sub>s</sub>=0.49), and <i>x</i> ray (<i>r</i><sub>s</sub>=0.35). Similar correlations were found for SF-36 physical functioning. Activity limitation and participation restriction dimensions are also related: the HAQ correlates well with SF-36 role-physical (<i>r</i><sub>s</sub>=−0.53) and SF-36 social functioning (<i>r</i><sub>s</sub>=−0.43); SF-36 physical functioning correlates similarly. For impairment and participation restriction dimensions only SF-36 bodily pain is substantially correlated (<i>r</i><sub>s</sub>=0.47 and 0.48) with SF-36 role-physical, after correcting for the influence of the activity limitation dimension (HAQ and SF-36 physical functioning). Conclusions: In this cross sectional study of patients with RA, impairments are associated with activity limitations, and activity limitations are associated with participation restrictions. Pain is the only impairment directly associated with participation restrictions. Based on the results of this study, it is strongly recommended that the ICIDH-2 framework is used in clinical trials and observational studies including the assessment of disease consequences in RA.